-
Je něco špatně v tomto záznamu ?
The effects of growth hormone status on circulating levels of vascular growth factors
J.V. Silha, M. Krsek, V. Hana, J. Marek, V. Weiss, J. Jezkova, M. Rosicka, Z. Jarkovska, L.J. Murphy
Jazyk angličtina Země Anglie, Velká Británie
Typ dokumentu práce podpořená grantem
Grantová podpora
NB7569
MZ0
CEP - Centrální evidence projektů
Digitální knihovna NLK
Plný text - Část
Zdroj
NLK
Wiley Online Library (archiv)
od 1997-01-01 do 2012-12-31
PubMed
15963066
Knihovny.cz E-zdroje
- MeSH
- akromegalie krev patofyziologie MeSH
- angiopoetin-2 krev MeSH
- dospělí MeSH
- endostatiny krev MeSH
- hepatocytární růstový faktor krev MeSH
- inhibitory angiogeneze krev MeSH
- insulinu podobný růstový faktor I analýza MeSH
- látky indukující angiogenezi * krev MeSH
- lidé středního věku MeSH
- lidé MeSH
- lidský růstový hormon fyziologie nedostatek MeSH
- menopauza fyziologie MeSH
- pankreatická ribonukleasa krev MeSH
- sexuální faktory MeSH
- vaskulární endoteliální růstový faktor A krev MeSH
- vaskulární endoteliální růstový faktor C krev MeSH
- vaskulární endoteliální růstový faktor D krev MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- ženské pohlaví MeSH
- Publikační typ
- práce podpořená grantem MeSH
BACKGROUND: Vascular growth factors are important not only in angiogenesis but also for the maintenance of normal endothelial integrity and function. Elevated levels of vascular endothelial growth factor (VEGF), angiopoietin-2, hepatocyte growth factor (HGF), endostatin and angiogenin have been associated with endothelial dysfunction and atherosclerosis. Both acromegaly and growth hormone deficiency (GHD) are associated with endothelial dysfunction and changes in blood vessel morphology. AIM: To investigate the effect of GH status on the circulating levels of angiogenic factors. DESIGN: We measured the levels of six endothelial growth modulators, four angiogenic growth factors and two inhibitors of angiogenesis in 35 untreated acromegalics, 36 untreated GH-deficient subjects and 101 normal control subjects. Fifteen GH-deficient subjects were also studied before and 1 year after treatment with GH. RESULTS: Mean angiogenin concentrations were increased in acromegaly and decreased in GH-deficient subjects compared to control subjects. Endostatin levels showed a similar pattern although the elevated levels in acromegalic subjects did not achieve statistical significance. Angiogenin and endostatin levels both correlated significantly with IGF-I levels (R = 0.61, P < 0.001 and R = 0.22, P < 0.01, respectively). The relationship between angiogenin and IGF-I levels remained significant even after correction for gender, age, body mass index (BMI) and insulin resistance. There were no significant differences in the levels of HGF, VEGF, VEGF-C or angiopoietin-2 between the three groups. VEGF-D levels were elevated in both acromegalic and GH-deficient male subjects. A similar pattern was apparent in female subjects. After GH treatment, a significant reduction in VEGF-D levels and a significant rise in endostatin levels were observed in GH-deficient subjects. A nonsignificant increase in angiogenin levels was also observed. CONCLUSION: These data indicate that significant perturbations in the levels of vascular growth modulators are present in both acromegaly and GHD. While changes in endostatin and angiogenin levels appear to correlate with IGF-I levels, VEGF-D levels show similar perturbations in both acromegaly and GHD. Further studies are required to determine the relationship of the perturbations to endothelial dysfunction in these conditions.
3rd Department of Internal Medicine 1st Faculty of Medicine Charles University Prague Czech Republic
Department of Physiology and Internal Medicine University of Manitoba Winnipeg Canada
- 000
- 00000naa a2200000 a 4500
- 001
- bmc13014843
- 003
- CZ-PrNML
- 005
- 20190104125501.0
- 007
- ta
- 008
- 130417s2005 enk f 000 0|eng||
- 009
- AR
- 035 __
- $a (PubMed)15963066
- 040 __
- $a ABA008 $d ABA008 $e AACR2 $b cze
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Silha, J.V. $u Department of Physiology and Internal Medicine, University of Manitoba, Winnipeg, Canada.
- 245 14
- $a The effects of growth hormone status on circulating levels of vascular growth factors / $c J.V. Silha, M. Krsek, V. Hana, J. Marek, V. Weiss, J. Jezkova, M. Rosicka, Z. Jarkovska, L.J. Murphy
- 520 9_
- $a BACKGROUND: Vascular growth factors are important not only in angiogenesis but also for the maintenance of normal endothelial integrity and function. Elevated levels of vascular endothelial growth factor (VEGF), angiopoietin-2, hepatocyte growth factor (HGF), endostatin and angiogenin have been associated with endothelial dysfunction and atherosclerosis. Both acromegaly and growth hormone deficiency (GHD) are associated with endothelial dysfunction and changes in blood vessel morphology. AIM: To investigate the effect of GH status on the circulating levels of angiogenic factors. DESIGN: We measured the levels of six endothelial growth modulators, four angiogenic growth factors and two inhibitors of angiogenesis in 35 untreated acromegalics, 36 untreated GH-deficient subjects and 101 normal control subjects. Fifteen GH-deficient subjects were also studied before and 1 year after treatment with GH. RESULTS: Mean angiogenin concentrations were increased in acromegaly and decreased in GH-deficient subjects compared to control subjects. Endostatin levels showed a similar pattern although the elevated levels in acromegalic subjects did not achieve statistical significance. Angiogenin and endostatin levels both correlated significantly with IGF-I levels (R = 0.61, P < 0.001 and R = 0.22, P < 0.01, respectively). The relationship between angiogenin and IGF-I levels remained significant even after correction for gender, age, body mass index (BMI) and insulin resistance. There were no significant differences in the levels of HGF, VEGF, VEGF-C or angiopoietin-2 between the three groups. VEGF-D levels were elevated in both acromegalic and GH-deficient male subjects. A similar pattern was apparent in female subjects. After GH treatment, a significant reduction in VEGF-D levels and a significant rise in endostatin levels were observed in GH-deficient subjects. A nonsignificant increase in angiogenin levels was also observed. CONCLUSION: These data indicate that significant perturbations in the levels of vascular growth modulators are present in both acromegaly and GHD. While changes in endostatin and angiogenin levels appear to correlate with IGF-I levels, VEGF-D levels show similar perturbations in both acromegaly and GHD. Further studies are required to determine the relationship of the perturbations to endothelial dysfunction in these conditions.
- 590 __
- $a bohemika - dle Pubmed
- 650 02
- $a akromegalie $x krev $x patofyziologie $7 D000172
- 650 02
- $a dospělí $7 D000328
- 650 12
- $a látky indukující angiogenezi $x krev $7 D043925
- 650 02
- $a inhibitory angiogeneze $x krev $7 D020533
- 650 02
- $a angiopoetin-2 $x krev $7 D042702
- 650 02
- $a endostatiny $x krev $7 D043169
- 650 02
- $a ženské pohlaví $7 D005260
- 650 02
- $a hepatocytární růstový faktor $x krev $7 D017228
- 650 02
- $a lidský růstový hormon $x fyziologie $x nedostatek $7 D019382
- 650 02
- $a lidé $7 D006801
- 650 02
- $a insulinu podobný růstový faktor I $x analýza $7 D007334
- 650 02
- $a mužské pohlaví $7 D008297
- 650 02
- $a menopauza $x fyziologie $7 D008593
- 650 02
- $a lidé středního věku $7 D008875
- 650 02
- $a pankreatická ribonukleasa $x krev $7 D012259
- 650 02
- $a sexuální faktory $7 D012737
- 650 02
- $a vaskulární endoteliální růstový faktor A $x krev $7 D042461
- 650 02
- $a vaskulární endoteliální růstový faktor C $x krev $7 D042582
- 650 02
- $a vaskulární endoteliální růstový faktor D $x krev $7 D042643
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Kršek, Michal $7 xx0046428 $u Third Department of Internal Medicine, First Faculty of Medicine, Charles University, Prague, Czech Republic
- 700 1_
- $a Hána, Václav, $d 1956- $7 xx0018430 $u Third Department of Internal Medicine, First Faculty of Medicine, Charles University, Prague, Czech Republic
- 700 1_
- $a Marek, Josef, $d 1936-2019 $7 nlk19990073526 $u Third Department of Internal Medicine, First Faculty of Medicine, Charles University, Prague, Czech Republic
- 700 1_
- $a Weiss, Vladimír. $7 xx0185340 $u Third Department of Internal Medicine, First Faculty of Medicine, Charles University, Prague, Czech Republic
- 700 1_
- $a Ježková, Jana $7 xx0074177 $u Third Department of Internal Medicine, First Faculty of Medicine, Charles University, Prague, Czech Republic
- 700 1_
- $a Rosická, Martina $7 xx0061797 $u Third Department of Internal Medicine, First Faculty of Medicine, Charles University, Prague, Czech Republic
- 700 1_
- $a Jarkovská, Zuzana $7 xx0056683 $u Third Department of Internal Medicine, First Faculty of Medicine, Charles University, Prague, Czech Republic
- 700 1_
- $a Murphy, L.J. $u Department of Physiology and Internal Medicine, University of Manitoba, Winnipeg, Canada.
- 773 0_
- $t Clinical Endocrinology $x 0300-0664 $g Roč. 63, č. 1 (2005), s. 79-86 $p Clin Endocrinol (Oxf) $w MED00009474
- 910 __
- $a ABA008 $b B 1409 $y 3 $z 0
- 990 __
- $a 20130417133503 $b ABA008
- 991 __
- $a 20190104125657 $b ABA008
- 999 __
- $a ok $b bmc $g 977874 $s 813149
- BAS __
- $a 3
- BMC __
- $a 2005 $b 63 $c 1 $d 79-86 $i 0300-0664 $m Clinical endocrinology $x MED00009474 $n Clin Endocrinol (Oxf)
- GRA __
- $a NB7569 $p MZ0
- LZP __
- $a NLK 2013-04/lpbo